Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine

Ailani J, Burch RC, Robbins MS. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021–39.

Article  Google Scholar 

de Vries T, Villalón CM, MaassenVanDenBrink A. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol Ther. 2020;211: 107528.

Article  Google Scholar 

Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17(8):501–14.

Article  Google Scholar 

Robbins MS. Diagnosis and management of headache: a review. JAMA. 2021;325(18):1874–85.

Article  Google Scholar 

Sacco S, Lampl C, Amin FM, et al. European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain. 2022;23(1):133.

Article  CAS  Google Scholar 

Dodick DW, Shewale AS, Lipton RB, et al. Migraine patients with cardiovascular disease and contraindications: an analysis of real-world claims data. J Prim Care Community Health. 2020. https://doi.org/10.1177/2150132720963680.

Article  Google Scholar 

Martelletti P, Luciani M, Spuntarelli V, et al. Deprescribing in migraine. Expert Opin Drug Saf. 2021;20(6):623–5.

Article  Google Scholar 

Lionetto L, Capi M, Curto M, et al. Rimegepant. Calcitonin gene-related peptide (CGRP) receptor antagonist: treatment of migraine. Drugs Future. 2019;44(8):635.

Article  Google Scholar 

Negro A, Martelletti P. Rimegepant for the treatment of migraine. Drugs Today (Barc). 2020;56(12):769–80.

Article  CAS  Google Scholar 

Biohaven Pharmaceuticals. NURTEC ODT (rimegepant) orally disintegrating tablets, for sublingual or oral use: US prescribing information. 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ef08e09-1098-35cc-e053-2a95a90a3e1d. Accessed 23 Jan 2023.

European Medicines Agency. VYDURA 75 mg oral lyophilisate: EU summary of product characteristics. 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/vydura. Accessed 23 Jan 2023.

Edvinsson L. Rimegepant oral disintegrating tablet for migraine. Lancet. 2019;394(10200):711–2.

Article  Google Scholar 

Pan KS, Siow A, Hay DL, et al. Antagonism of CGRP signaling by rimegepant at two receptors. Front Pharmacol. 2020;11:1240.

Article  CAS  Google Scholar 

Hage La Cour S, Juhler K, Kogelman LJA, et al. Characterization of erenumab and rimegepant on calcitonin gene-related peptide induced responses in Xenopus Laevis oocytes expressing the calcitonin gene-related peptide receptor and the amylin-1 receptor. J Headache Pain. 2022;23(1):59.

Article  CAS  Google Scholar 

Conway C, Dubowchik G, Croop R, et al. Phase 1 and 2 safety, tolerability and pharmacokinetics of single and multiple dose rimegepant as compared to the predicted clinically efficacious dose range [abstract no. 2145 plus poster P13.004]. Neurology. 2020;94(15 Suppl.).

Tong G, Savant I, Jariwala N, et al. Phase I single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of BMS-927711 in healthy subjects. J Headache Pain. 2013;14(Suppl. 1):P118.

Article  Google Scholar 

Conway C, Dubowchik GM, Coric V. Rimegepant and BHV-3500, small molecule CGRP receptor antagonists, exhibit no active vasoconstrictive properties in ex-vivo human coronary or cerebral arteries [abstract no. LBOR-08 plus poster]. Headache. 2018;58(8):1295.

Google Scholar 

Conway C, Croop R, Dubowchik GM, et al. Cardiovascular safety of rimegepant 75 mg in 3 randomized clinical trials and systematic evaluations from in vitro, ex vivo, and in vivo noncilincal assays [abstract no. P237LB plus poster]. Headache. 2019;59(Suppl. 1):176.

Google Scholar 

Hanna M, Coric V, Stringfellow J, et al. Rimegepant has no clinically relevant effect on ECG parameters at therapeutic and supratherapeutic doses: a thorough QT study versus placebo and moxifloxacin in healthy subjects [abstract no. 2117 plus poster P6.003]. Neurology. 2020;94(15 Suppl.):2117.

Google Scholar 

Croop R, Ivans A, Anderson MS, et al. A phase 1 randomized study of hemodynamic effects and pharmacokinetic interactions during concomitant use of rimegepant and sumatriptan in healthy adults. Cephalalgia Rep. 2021;4:1–10.

Google Scholar 

Croop R, Ivans A, Anderson M, et al. A phase 1 study to evaluate the bioequivalence of oral tablet and orally dissolving tablet formulations of rimegepant, a small molecule CGRP receptor antagonist [abstract no. poster MTIS2018-170]. In: 17th Biennial Migraine Trust International Symposium. 2018.

Ivans A, Stringfellow J, Coric V, et al. Rimegepant 75 mg exposure, safety, and tolerability are similar in elderly and nonelderly adults: a phase 1, open-label, parallel-group, single-dose study [abstract no. 2101]. Neurology. 2020;94(15 Suppl.).

Li Y, Wang X, Ballesteros-Perez A, et al. A phase 1, randomized, placebo-controlled, single-and multiple-dose, double-blind study to evaluate the pharmacokinetics and safety of rimegepant orally disintegrating tablets 75 mg in healthy Chinese adults [abstract no. poster LB-P-19]. Headache. 2022;62(7):922.

Google Scholar 

Ivans A, Stringfellow J, Coric V, et al. Results of a phase 1, open-label, single-dose, parallel-group study of rimegepant 75 mg in subjects with hepatic impairment [abstract no. 2126 plus poster P1.006]. Neurology. 2020;94(15 Suppl.).

Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737–45.

Article  CAS  Google Scholar 

Lipton RB, Conway CM, Stock EG, et al. Efficacy, safety, and tolerability of rimegepant 75 mg, an oral CGRP receptor antagonist, for the acute treatment of migraine: results from a double-blind, randomized, placebo-controlled trial, study 301 [abstract no. PS123LB plus poster]. Headache. 2018;58(8):1336–7.

Google Scholar 

Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381(2):142–9.

Article  CAS  Google Scholar 

Yu S, Kim B-K, McGrath D, et al. Efficacy, safety, and tolerability of rimegepant 75 mg orally disintegrating tablet for the acute treatment of migraine: results from a phase 3, double-blind, randomized, placebo-controlled trial in adults from China and Korea [abstract no. LB-P-20 plus poster]. In: The American Headache Society's Annual Scientific Meeting. 2022.

Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34(2):114–25.

Article  Google Scholar 

Jensen C, Lipton R, Blumenfeld A, et al. Rimegepant for the acute treatment of migraine in patients with a history of triptan treatment failure: pooled results from 3 phase 3 clinical trials [abstract no. 4914]. Neurology. 2021;96(15 Suppl.).

McAllister P, Berman G, Kudrow D, et al. Rimegepant 75 mg demonstrates superiority to placebo on nausea freedom: results from a post hoc pooled analysis of 3 phase 3 trials in the acute treatment of migraine [abstract no. 2402]. Neurology. 2020;94(15 Suppl.).

Levin M, Buse D, Blumenfeld A, et al. Rimegepant 75 mg is effective for the acute treatment of migraine regardless of attack frequency: results from 3 phase 3 trials [abstract no. 1212]. Neurology. 2020;94(15 Suppl.).

Pavlovic J, Dodick D, Newman L, et al. Rimegepant is effective for the acute treatment of migraine in subjects taking concurrent preventive medication: results from 3 phase 3 trials [abstract no. 2091]. Neurology. 2020;94(15 Suppl.).

Pavlovic J, Dodick D, Friedman D, et al. Rimegepant 75 mg provides early and sustained relief of migraine with a single dose: results from 3 phase 3 clinical trials [abstract no. 2366]. Neurology. 2020;94(15 Suppl.).

Smith T, McAllister P, Berman G, et al. Low rates of rescue medication usage in subjects treated with a single dose of rimegepant 75 mg for the acute treatment of migraine:results from 3 phase 3 clinical trials [abstract no. 2342 plus poster]. Neurology. 2021;96(15 Suppl.).

Mohajer A, Scripture J, Harris L, et al. Decreased opioid use in migraine patients following rimegepant initiation: a real-world analysis [abstract no. POSC170 plus poster]. Value Health. 2022;25(Suppl. 1):S134.

Article  Google Scholar 

Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51–60.

Article  CAS  Google Scholar 

Lipton RB, Croop R, Jensen CM, et al. Rapid decrease in migraine days with rimegepant: results from a post hoc analysis of a phase 2/3, randomized, double-blind, placebo-controlled trial [abstract no. P­148 plus poster]. Headache. 2021;61(Suppl. 1):138–9.

Google Scholar 

Jensen C, Thiry A, Kim E, et al. Acute treatment with oral rimegepant 75 mg reduces migraine-related disability in adults with and without a history of triptan treatment failure: results from a one-year, open-label safety study [abstract no. P2-2.002 plus poster 873]. Neurology. 2022;98(18 Suppl.).

Johnston KM, L’Italien G, Popoff E, et al. Mapping migraine-specific quality of life to health state utilities in patients receiving rimegepant. Adv Ther. 2021;38(10):5209–20.

Article  CAS  Google Scholar 

Ailani J, Kudrow D, Smith TR, et al. Effects of rimegepant 75 mg on monthly migraine days: a 52-week, open-label extension study [abstract no. P-162]. Headache. 2022;62(Suppl. 1):139–40.

Google Scholar 

Johnston K, Harris L, Powell L, et al. Monthly migraine days, tablet utilization, and quality of life associated with rimegepant: post hoc results from an open label safety study (BHV3000-201). J Headache Pain. 2022;23:10.

Article  CAS  Google Scholar 

Pavlovic JM, Turner IM, Winner P, et al. Long-term preventive and acute treatment of migraine with rimegepant improves health related quality of life [abstract no. P-128]. Headache. 2022;62(Suppl. 1):112–3.

Google Scholar 

L'Italien G, Popoff E, Harris L, et al. Acute treatment with rimegepant 75 mg confers clinically relevant improvement in lost time (days) due to migraine: results from a 1-year, open-label safety study (bhv3000-201) [abstract no. 4945 plus poster]. Neurology. 2021;96(15 Suppl.).

Lipton RB, McAllister P, Turner IM, et al. Effect of long-term preventive treatment with oral rimegepant 75 mg on migraine-related disability: a 52-week, open-label extension study [abstract no. P­158]. Headache. 2022;62(Suppl. 1):136–7.

Google Scholar 

Mullin K, Pavlovic JM, Hutchinson S, et al. Medication preference, satisfaction, and clinical improvement among adults receiving long-term treatment with rimegepant for migraine [abstract no. P-130]. Headache. 2022;62(Suppl. 1):114.

Google Scholar 

Turner IM, Pavlovic JM, Lipton RB, et al. Preference for rimegepant and improved clinical global impression of change among adults with a history of triptan treatment failure: results from a long-term open-label safety study [abstract no. P­147]. Headache. 2021;61(Suppl. 1):137–8.

Google Scholar 

Kudrow D, Mullin K, Berman G, et al. Long-term use of rimegepant 75 mg for the acute treatment of migraine reduces use of analgesics and antiemetics [abstract no. 5072 plus poster]. Neurology. 2021;96(15 Suppl.).

Hutchinson S, Lipton R, Stock E, et al. Three phase 3 trials show the safety and tolerability profiles of rimegepant 75 mg were similar to placebo [abstract no. poster IP21]. In: Headache Cooperative of the Pacific Winter Conference. 2020.

Schim J, Hutchinson S, Lipton R, et al. Rimegepant 75 mg demonstrates safety and tolerability similar to placebo with no effects of age, sex, or race in 3 phase 3 trials [abstract no. 1609]. Neurology. 2020;94(15 Suppl.).

Croop R, Shiovitz T, Khan A, et al. An open-label, intermediate-sized, expanded access protocol of rimegepant in the acute treatment of migraine [abstract no. P2-2.006 plus poster 874]. Neurology. 2022;98(18 Suppl.).

Croop R, Berman G, Kudrow D, et al. Long-term safety of rimegepant 75 mg for the acute treatment of migraine (study 201) [abstract no. 4829]. Neurology. 2020;94(15 Suppl.).

Lipton RB, Kudrow D, Smith TR, et al. Safety and tolerability of rimegepant every other day for preventive treatment of migraine plus as-needed for acute treatment of migraine: results from a 52-week, open-label extension study [abstract no. IOR­09]. Headache. 2022;62(Suppl. 1):99.

Google Scholar 

Mullin K, Hutchinson S, Smith T, et al. Long-term safety of rimegepant 75 mg for the acute treatment of migraine in adults with a history of triptan treatment failure [abstract no. 5142 plus poster]. Neurology. 2021;96(15 Suppl.).

Mullin K, Hutchinson S, Smith T, et al. Rimegepant 75 mg for the acute treatment of migraine in adults with frequent migraine: long-term safety and clinical improvement versus baseline [abstract no. 5054]. Neurology. 2021;96(15 Suppl.).

Schim J, Hutchinson S, Lipton R, et al. Rimegepant is safe and tolerable for the acute treatment of migraine in patients using preventive migraine medications: results from a long-term open-label safety study [abstract no. 2370 plus poster]. Neurology. 2021;96(15 Suppl.).

Buse DC, Baskin SM, Lipton RB, et al. Rimegepant 75 mg is safe and well tolerated for the acute treatment of migraine in adults with a history of depression or anxiety: results from a long-term open-label safety study (study 201) [abstract plus poster]. Headache. 2020;60(Suppl. 1):120–1.

Google Scholar 

Baskin SM, Buse DC, Jensen CM, et al. Rimegepant 75 mg is safe and well tolerated for the acute treatment of migraine in adults using selective serotonin reuptake inhibitors (SSRIs) and other antidepressants: results from a long-term, open-label safety study (study 201) [abstract no. plus poster]. Headache. 2020;60(Suppl. 1):120.

Google Scholar 

Hutchinson S, Schim J, Lipton R, et al. Oral rimegepant 75 mg is safe and well tolerated in adults with migraine and cardiovascular risk factors: results of a multicenter, long-term, open-label safety study [abstract no. 1995 plus poster]. Neurology. 2021;96(15 Suppl.).

Johnson B, Freitag FG. New approaches to shifting the migraine treatment paradigm. Front Pain Res (Lausanne). 2022;3: 873179.

Article  Google Scholar 

Berger AA, Winnick A, Carroll AH, et al. Rimegepant for the treatment of migraine. Health Psychol Res. 2022;10(5):38534.

Article  Google Scholar 

Edvinsson L. Oral rimegepant for migraine prevention. Lancet. 2021;397(10268):4–5.

Article  Google Scholar 

Johnston K, Popoff E, Deighton A, et al. Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis. Expert Rev Pharmacoecon Outcomes Res. 2022;22(1):155–66.

Article  Google Scholar 

Polavieja P, Belger M, Venkata SK, et al. Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings. J Headache Pain. 2022;23(76):1–14.

Google Scholar 

Singh A, Gupta D, Singh A. Ditans vs gepants: a systematic review and indirect network meta-analysis for comparative analysis of efficacy and safety. Neurol India. 2021;69(Suppl. 1):S43–50.

Article  Google Scholar 

Yang CP, Liang CS, Chang CM, et al. Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(10):e2128544 (1–15).

Article  Google Scholar 

Popoff E, Powell L, Rahim T, et al. Rimegepant versus atogepant and monoclonal antibody treatments for the prevention of migraine: a systematic literature review and network meta-analysis [abstract no. P-145 plus poster]. Headache. 2021;61(Suppl. 1):145–6.

留言 (0)

沒有登入
gif